QLT to Appoint Glen Ibbott as Interim Chief Financial Officer
January 05 2015 - 6:00AM
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company") today
announced that Mr. Glen Ibbott has been appointed as the Interim
Chief Financial Officer of the Company effective January 26, 2015,
the resignation date of the Company's current Chief Financial
Officer. In order to efficiently transition to the role of the
Interim Chief Financial Officer, Mr. Ibbott has been appointed Vice
President, Finance of the Company effective today.
Mr. Ibbott has over 15 years of experience leading finance teams
in globally operating public companies. Most recently, he served as
Vice President, Finance for Nordion Inc., a global health science
company, which, until its acquisition by Sterigenics International
LLC in August 2014, was listed on both the New York Stock Exchange
and the Toronto Stock Exchange. Mr. Ibbott is a Chartered
Accountant and a Certified Public Accountant.
About QLT
QLT is a biotechnology company dedicated to the development and
commercialization of innovative ocular products that address the
unmet medical needs of patients and clinicians worldwide. We are
focused on developing our synthetic retinoid program for the
treatment of certain inherited retinal diseases.
QLT's head office is based in Vancouver, Canada and the Company
is publicly traded on NASDAQ Stock Market (symbol: QLTI) and the
Toronto Stock Exchange (symbol: QLT). For more information about
the Company's products and developments, please visit our web site
at www.qltinc.com.
Certain statements in this press release constitute "forward
looking statements" of QLT within the meaning of the Private
Securities Litigation Reform Act of 1995 and constitute "forward
looking information" within the meaning of applicable Canadian
securities laws. Forward looking statements include, but are not
limited to: statements which contain language such as: "assuming,"
"prospects," "goal," "future," "projects," "potential," "could,"
"believes," "expects"; "hopes" and "outlook." Forward-looking
statements are predictions only which involve known and unknown
risks, uncertainties and other factors that may cause actual
results to be materially different from those expressed in such
statements. Many such risks, uncertainties and other factors are
taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the following
risks, uncertainties and other factors: the effect that QLT's
announcements and actions will have on the market price of our
securities; factors described in detail in QLT's Annual Report on
Form 10K, Quarterly Reports on Form 10Q and other filings with the
U.S. Securities and Exchange Commission and Canadian securities
regulatory authorities. Forward-looking statements are based on the
current expectations of QLT and QLT does not assume any obligation
to update such information to reflect later events or developments
except as required by law.
CONTACT: QLT Inc. Contacts:
Investor & Media Relations
Andrea Rabney or David Pitts
Argot Partners
212-600-1902
andrea@argotpartners.com
david@argotpartners.com
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Apr 2024 to May 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From May 2023 to May 2024